| scholarly article | Q13442814 |
| P50 | author | James Januzzi | Q63144011 |
| P2093 | author name string | Robert E Gerszten | |
| Marielle Scherrer-Crosbie | |||
| Bonnie Ky | |||
| Michael H Picard | |||
| Elkan F Halpern | |||
| Heloisa Sawaya | |||
| Igal A Sebag | |||
| Irene Kuter | |||
| Jonathan Passeri | |||
| Jose Banchs | |||
| Joseph R Carver | |||
| Juan Carlos Plana | |||
| Mary Putt | |||
| Randolph P Martin | |||
| Victor Cohen | |||
| Virginia Shalkey Hahn | |||
| P2860 | cites work | Cardiac dysfunction in the trastuzumab clinical trials experience | Q28204298 |
| Cancer therapy-induced cardiotoxicity: basic mechanisms and potential cardioprotective therapies | Q30426853 | ||
| Effects by doxorubicin on the myocardium are mediated by oxygen free radicals | Q32049408 | ||
| Left ventricular dysfunction predicted by early troponin I release after high-dose chemotherapy | Q33180853 | ||
| Prognostic value of troponin I in cardiac risk stratification of cancer patients undergoing high-dose chemotherapy | Q33202989 | ||
| Adjuvant trastuzumab in the treatment of her-2-positive early breast cancer: a meta-analysis of published randomized trials | Q33293618 | ||
| Trastuzumab-Induced Cardiotoxicity: Clinical and Prognostic Implications of Troponin I Evaluation | Q33647686 | ||
| Plasma concentrations of angiogenic/anti-angiogenic factors have prognostic value in women presenting with suspected preeclampsia to the obstetrical triage area: a prospective study | Q34119026 | ||
| Early increases in multiple biomarkers predict subsequent cardiotoxicity in patients with breast cancer treated with doxorubicin, taxanes, and trastuzumab | Q34855776 | ||
| Placental growth factor regulates cardiac adaptation and hypertrophy through a paracrine mechanism | Q35135394 | ||
| A cardiac myocyte vascular endothelial growth factor paracrine pathway is required to maintain cardiac function | Q35895986 | ||
| Risk of heart failure in breast cancer patients after anthracycline and trastuzumab treatment: a retrospective cohort study | Q36207305 | ||
| Molecular and cellular mechanisms of anthracycline cardiotoxicity | Q36891743 | ||
| Assessment of echocardiography and biomarkers for the extended prediction of cardiotoxicity in patients treated with anthracyclines, taxanes, and trastuzumab | Q36988278 | ||
| Early detection and prediction of cardiotoxicity in chemotherapy-treated patients | Q36988282 | ||
| Efficacy, safety, and biomarkers of neoadjuvant bevacizumab, radiation therapy, and fluorouracil in rectal cancer: a multidisciplinary phase II study | Q37242288 | ||
| Growth differentiation factor (GDF)-15 blocks norepinephrine-induced myocardial hypertrophy via a novel pathway involving inhibition of epidermal growth factor receptor transactivation | Q37683299 | ||
| Cardiovascular side effects of cancer therapies: a position statement from the Heart Failure Association of the European Society of Cardiology | Q37822215 | ||
| Growth differentiation factor 15 in cardiovascular diseases: from bench to bedside | Q37896086 | ||
| Doxorubicin-induced cardiomyopathy: from molecular mechanisms to therapeutic strategies | Q37998724 | ||
| Emerging paradigms in cardiomyopathies associated with cancer therapies | Q38132645 | ||
| Growth-differentiation factor-15 in heart failure | Q39960475 | ||
| Prognostic value and echocardiographic determinants of plasma myeloperoxidase levels in chronic heart failure | Q40203262 | ||
| Elevated placental growth factor levels are associated with adverse outcomes at four-year follow-up in patients with acute coronary syndromes | Q42166762 | ||
| Trastuzumab-associated cardiac adverse effects in the herceptin adjuvant trial. | Q42626922 | ||
| Incidence of heart failure or cardiomyopathy after adjuvant trastuzumab therapy for breast cancer | Q43752699 | ||
| N-terminal pro-B-type natriuretic peptide after high-dose chemotherapy: a marker predictive of cardiac dysfunction? | Q44090143 | ||
| Prognostic value of placental growth factor in patients with acute chest pain | Q47237254 | ||
| Small-sample performance of the robust score test and its modifications in generalized estimating equations | Q48483790 | ||
| Recommendations for chamber quantification: a report from the American Society of Echocardiography's Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardio | Q57217547 | ||
| Suppression of doxorubicin cardiotoxicity by overexpression of catalase in the heart of transgenic mice | Q71119918 | ||
| Neuregulin activation of ErbB receptors in vascular endothelium leads to angiogenesis | Q73278904 | ||
| Neuregulin-1 beta attenuates doxorubicin-induced alterations of excitation-contraction coupling and reduces oxidative stress in adult rat cardiomyocytes | Q79148148 | ||
| The inhibitory effects of trastuzumab on corneal neovascularization | Q82827894 | ||
| Acute cardiotoxic effects of adjuvant trastuzumab treatment and its relation to oxidative stress | Q88029425 | ||
| P433 | issue | 9 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | doxorubicin | Q18936 |
| biomarker | Q864574 | ||
| P304 | page(s) | 1164-1172 | |
| P577 | publication date | 2015-07-27 | |
| P1433 | published in | Clinical Chemistry | Q849687 |
| P1476 | title | Longitudinal Changes in Multiple Biomarkers Are Associated with Cardiotoxicity in Breast Cancer Patients Treated with Doxorubicin, Taxanes, and Trastuzumab | |
| P478 | volume | 61 |
| Q99237996 | A Prospective Study of Early Radiation Associated Cardiac Toxicity Following Neoadjuvant Chemoradiation for Distal Esophageal Cancer |
| Q38747992 | Alternative Biomarkers for Combined Biology |
| Q33658456 | Anthracycline induced cardiotoxicity: biomarkers and "Omics" technology in the era of patient specific care |
| Q88868148 | Biomarker Discovery in Cardio-Oncology |
| Q39053477 | Biomarkers for monitoring chemotherapy-induced cardiotoxicity |
| Q36451899 | Cancer Therapy-Related Cardiac Dysfunction and Heart Failure: Part 1: Definitions, Pathophysiology, Risk Factors, and Imaging |
| Q30276456 | Cancer treatment-related cardiac toxicity: prevention, assessment and management |
| Q38632789 | Cardiac Imaging: Multimodality Advances and Surveillance Strategies in Detection of Cardiotoxicity |
| Q92776906 | Cardio-Oncology at the Beginning of a New Decade |
| Q26750878 | Cardio-oncology: Concepts and practice |
| Q38657849 | Cardio-oncology: Gaps in Knowledge, Goals, Advances, and Educational Efforts |
| Q91650757 | Cardiotoxicity of Anthracyclines |
| Q50045986 | Cardiovascular Disease and Breast Cancer: Where These Entities Intersect: A Scientific Statement From the American Heart Association. |
| Q92776949 | Changes in Cardiovascular Biomarkers With Breast Cancer Therapy and Associations With Cardiac Dysfunction |
| Q90640977 | Correlation of HER2 codon 655 polymorphism with cardiotoxicity risk in Chinese HER2-positive breast cancer patients undergoing epirubicin/cyclophosphamide followed by docetaxel plus trastuzumab adjuvant chemotherapy |
| Q33816471 | Creating a Biomarker Panel for Early Detection of Chemotherapy Related Cardiac Dysfunction in Breast Cancer Patients |
| Q92677814 | Doxorubicin-Induced Cardiomyopathy in Children |
| Q92533204 | HER2+ breast cancer treatment and cardiotoxicity: monitoring and management |
| Q26740352 | Heart failure in chemotherapy-related cardiomyopathy: Can exercise make a difference? |
| Q38868285 | High-sensitive cardiac troponin-I facilitates timely detection of subclinical anthracycline-mediated cardiac injury |
| Q90653004 | In Vivo Reactive Oxygen Species Detection With a Novel Positron Emission Tomography Tracer, 18F-DHMT, Allows for Early Detection of Anthracycline-Induced Cardiotoxicity in Rodents |
| Q90178681 | NT-proBNP correlates with LVEF decline in HER2-positive breast cancer patients treated with trastuzumab |
| Q58801798 | Oral Administration of Improves the Effect of Taxane on Preventing the Progression of Breast Cancer and Reduces Its Side Effects |
| Q92434457 | Pilot study of bevacizumab in combination with docetaxel and cyclophosphamide as adjuvant treatment for patients with early stage HER-2 negative breast cancer, including analysis of candidate circulating markers of cardiac toxicity: ICORG 08-10 tria |
| Q26768272 | Prevention of cardiac dysfunction during adjuvant breast cancer therapy (PRADA): a 2 × 2 factorial, randomized, placebo-controlled, double-blind clinical trial of candesartan and metoprolol |
| Q57821006 | Protecting the heart in cancer therapy |
| Q58693257 | Randomized study of doxorubicin-based chemotherapy regimens, with and without sildenafil, with analysis of intermediate cardiac markers |
| Q52364966 | Redefining biomarkers in heart failure. |
| Q36626934 | Roadmap for biomarkers of cancer therapy cardiotoxicity |
| Q55429574 | Role of Biomarkers in Prediction of Cardiotoxicity During Cancer Treatment. |
| Q38431519 | Short infusion of paclitaxel imbalances plasmatic lipid metabolism and correlates with cardiac markers of acute damage in patients with breast cancer |
| Q97544688 | The Role of Biomarkers in Cardio-Oncology |
| Q38728535 | The Role of Biomarkers in Detection of Cardio-toxicity |
| Q92980788 | The Role of Cardiovascular Imaging and Serum Biomarkers in Identifying Cardiotoxicity Related to Cancer Therapeutics |
| Q61454606 | The breast cancer patient in the cardioncology unit |
| Q50946920 | The interplay between genetic background and sexual dimorphism of doxorubicin-induced cardiotoxicity. |
| Q100418466 | The role of serum biomarkers in cancer patients receiving cardiotoxic cancer therapies: a position statement from the Cardio-Oncology Study Group of the Heart Failure Association and Cardio-Oncology Council of the European Society of Cardiology |
| Q89184149 | Update on Incorporating Biomarkers with Imaging Findings for the Detection and Management of Cardiotoxicity |
| Q39018351 | Using biomarkers to predict and to prevent cardiotoxicity of cancer therapy |
Search more.